Abbott Laboratories (ABT) analyst actions
Rating and price-target actions on ABT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ABT overview →
4 measured ABT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology | Press release | -0.10% | +0.15% | |
| Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease | Press release | +0.35% | +0.39% | |
| Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure | Press release | -0.26% | -0.65% | |
| Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression | Press release | -0.21% | -0.37% |
Keep exploring
More ABT: earnings → · SEC filings → · ABT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Intec Pharma Ltd (NTEC) | 437 | -0.26% | 36% |
| VALERITAS HOLDINGS (VLRX) | 437 | -0.35% | 28% |
| The Cigna Group (CI) | 435 | +0.10% | 58% |
| IMPRIMIS PHARMACEUTICALS (IMMY) | 435 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.